NCT05259605 Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
| NCT ID | NCT05259605 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,650 participants |
| Start Date | 2023-03-21 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,650 participants in total. It began in 2023-03-21 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
Eligibility Criteria
* Age ≥ legal age of consent * Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest * Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16. * Available MRI/CT scans from primary brain tumour at initial diagnosis * Patient's consent Deceased patient: The clinical data and/or biological material and/or CT/MRI/PET images can be accessed and used if at least one of the following three conditions is met: * The patient agreed beforehand in his/her lifetime to a further use of his/her data and/or biological material and/or CT/MRI/PET images, or, * There is consent of a relative to use data and/or biological material and/or CT/MRI/PET images of the deceased patient, or, * There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients). Additionally, in all cases the following three points need to be fulfilled: * No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT/MR/PET images for research purposes * A notification to an ethics committee for the re-use of these data, biological material and CT/MRI/PET images * Any other national requirements are fulfilled, if applicable
Contact & Investigator
Michael Weller
PRINCIPAL INVESTIGATOR
EORTC Study Coordinator
Frequently Asked Questions
Who can join the NCT05259605 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05259605 currently recruiting?
Yes, NCT05259605 is actively recruiting participants. Contact the research team at eortc@eortc.org for enrollment information.
Where is the NCT05259605 trial being conducted?
This trial is being conducted at Innsbruck, Austria, Vienna, Austria, Aalst, Belgium, Anderlecht, Belgium and 11 additional locations.
Who is sponsoring the NCT05259605 clinical trial?
NCT05259605 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC. The principal investigator is Michael Weller at EORTC Study Coordinator. The trial plans to enroll 1,650 participants.